Matches in Wikidata for { <http://www.wikidata.org/entity/Q95601629> ?p ?o ?g. }
- Q95601629 description "2020 nî lūn-bûn" @default.
- Q95601629 description "2020年の論文" @default.
- Q95601629 description "2020年学术文章" @default.
- Q95601629 description "2020年学术文章" @default.
- Q95601629 description "2020年学术文章" @default.
- Q95601629 description "2020年学术文章" @default.
- Q95601629 description "2020年学术文章" @default.
- Q95601629 description "2020年学术文章" @default.
- Q95601629 description "2020年學術文章" @default.
- Q95601629 description "2020年學術文章" @default.
- Q95601629 description "2020年學術文章" @default.
- Q95601629 description "2020年學術文章" @default.
- Q95601629 description "2020年學術文章" @default.
- Q95601629 description "2020년 논문" @default.
- Q95601629 description "article científic" @default.
- Q95601629 description "article scientific" @default.
- Q95601629 description "article scientifique" @default.
- Q95601629 description "articol științific" @default.
- Q95601629 description "articolo scientifico" @default.
- Q95601629 description "artigo científico" @default.
- Q95601629 description "artigo científico" @default.
- Q95601629 description "artigo científico" @default.
- Q95601629 description "artikel ilmiah" @default.
- Q95601629 description "artikull shkencor" @default.
- Q95601629 description "artikulong pang-agham" @default.
- Q95601629 description "artykuł naukowy" @default.
- Q95601629 description "artículo científico publicado en 2020" @default.
- Q95601629 description "artículu científicu" @default.
- Q95601629 description "bilimsel makale" @default.
- Q95601629 description "bài báo khoa học" @default.
- Q95601629 description "naučni članak" @default.
- Q95601629 description "scienca artikolo" @default.
- Q95601629 description "scientific article published on 22 April 2020" @default.
- Q95601629 description "scientific article published on 22 April 2020" @default.
- Q95601629 description "scientific article published on 22 April 2020" @default.
- Q95601629 description "teaduslik artikkel" @default.
- Q95601629 description "tieteellinen artikkeli" @default.
- Q95601629 description "tudományos cikk" @default.
- Q95601629 description "vedecký článok" @default.
- Q95601629 description "vetenskaplig artikel" @default.
- Q95601629 description "videnskabelig artikel udgivet 22. april 2020" @default.
- Q95601629 description "vitenskapelig artikkel" @default.
- Q95601629 description "vitskapeleg artikkel" @default.
- Q95601629 description "vědecký článek" @default.
- Q95601629 description "wetenschappelijk artikel" @default.
- Q95601629 description "wissenschaftlicher Artikel" @default.
- Q95601629 description "επιστημονικό άρθρο" @default.
- Q95601629 description "мақолаи илмӣ" @default.
- Q95601629 description "наукова стаття, опублікована у квітні 2020" @default.
- Q95601629 description "научна статия" @default.
- Q95601629 description "научная статья" @default.
- Q95601629 description "научни чланак" @default.
- Q95601629 description "научни чланак" @default.
- Q95601629 description "מאמר מדעי" @default.
- Q95601629 description "مقالة علمية نشرت في 22 أبريل 2020" @default.
- Q95601629 description "২২ এপ্রিল ২০২০-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
- Q95601629 description "บทความทางวิทยาศาสตร์" @default.
- Q95601629 description "სამეცნიერო სტატია" @default.
- Q95601629 name "Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics" @default.
- Q95601629 name "Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics" @default.
- Q95601629 type Item @default.
- Q95601629 label "Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics" @default.
- Q95601629 label "Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics" @default.
- Q95601629 prefLabel "Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics" @default.
- Q95601629 prefLabel "Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics" @default.
- Q95601629 P1476 Q95601629-CC9F0FB4-7BFE-4EBB-AEF8-5BA2314C59BD @default.
- Q95601629 P2093 Q95601629-1474E90A-0B40-4E3B-9E59-31415C6FCB18 @default.
- Q95601629 P2093 Q95601629-7A1D4877-BCC4-47DC-B2F5-48E68D1FD460 @default.
- Q95601629 P2093 Q95601629-9E92F652-D773-419A-998B-E1741491F35D @default.
- Q95601629 P2093 Q95601629-CB89314D-E12E-4DF5-B07D-77792860DDAD @default.
- Q95601629 P2093 Q95601629-DB877B17-8791-48E7-B190-C5ED9B94C7BB @default.
- Q95601629 P2860 Q95601629-A795B17C-1F29-46CB-88D8-323AFD235F6C @default.
- Q95601629 P31 Q95601629-2C3F9152-D535-48FA-9345-6691B9E8D17E @default.
- Q95601629 P356 Q95601629-E4BC8D38-12DB-4BE0-B992-6E70808ED445 @default.
- Q95601629 P50 Q95601629-1506ACB8-61F7-4500-883A-D2B9E13E1419 @default.
- Q95601629 P50 Q95601629-28BCD5C0-A9B8-4AD8-A707-287BB7DDFFF6 @default.
- Q95601629 P50 Q95601629-515A3B8C-49C9-44C5-888F-258F0AEB4A14 @default.
- Q95601629 P50 Q95601629-51CF55FF-070D-4A53-95C0-A4233DE26045 @default.
- Q95601629 P50 Q95601629-5E422A5F-CD36-4104-9F2D-BFD5902C8EED @default.
- Q95601629 P50 Q95601629-6F47603D-D93D-4E8C-8B6C-5E5EADCD97E1 @default.
- Q95601629 P50 Q95601629-92C8DCD2-ABCB-495D-AA4D-84D08364C18C @default.
- Q95601629 P50 Q95601629-9606574D-F6E7-488F-9F87-BE93F8DACB85 @default.
- Q95601629 P50 Q95601629-AAC2FF87-0BCE-45BE-83F1-2A4D6F78949B @default.
- Q95601629 P50 Q95601629-AB99886B-157F-4B4D-A146-EF2BB185CC9F @default.
- Q95601629 P50 Q95601629-ADE365CF-6A85-4D06-A5E0-934EEF7CBC33 @default.
- Q95601629 P50 Q95601629-B0BCD9CF-CABB-4C93-8FE3-2094244DEF8F @default.
- Q95601629 P50 Q95601629-BE06E120-2ADD-42DD-B541-45995E499622 @default.
- Q95601629 P50 Q95601629-BEC1E26B-6DEE-4C39-8F6C-3A682C924FB1 @default.
- Q95601629 P50 Q95601629-D775B74C-1511-4F12-B71D-0A4CE8BAE4E4 @default.
- Q95601629 P50 Q95601629-D82F8D55-9E73-4C18-A780-0C6CE375BD33 @default.
- Q95601629 P577 Q95601629-3118C72B-0E19-434C-B2F5-AD29DC6A6261 @default.
- Q95601629 P6179 Q95601629-CE03CC65-B97D-4D51-838C-F341973086A6 @default.
- Q95601629 P8299 Q95601629-83C0C7D4-BD02-4B9A-9CA5-4F236D583358 @default.
- Q95601629 P921 Q95601629-3DEB6E4B-E610-4881-8A56-7F8D8F226456 @default.
- Q95601629 P356 2020.04.16.20068379 @default.
- Q95601629 P1476 "Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics" @default.
- Q95601629 P2093 "Christopher David" @default.
- Q95601629 P2093 "David J Back" @default.
- Q95601629 P2093 "Patrick G Bray" @default.
- Q95601629 P2093 "Paul O'Neill" @default.